Israel Expected To OK 5-Year Drug Marketing Exclusivity
The cabinet will hasten approval of the recommendations of an interministerial committee for protecting intellectual property rights for pharmaceuticals, Globes, a business daily, reported on Wednesday.
The interministerial committee recommends setting marketing exclusivity in Israel for international pharmaceutical companies for non-patented ethical drugs, and for drugs whose patents have expired, due to prolonged clinical trials. The five-year exclusivity period will apply...
To view the full article, register now.